Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 6/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 5/20 | 0.41 |
| ▸ | ACE | P12821 | 4/20 | 0.41 |
| ▸ | CPA1 | P15085 | 3/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18129829 | 1.00 | PTPN1 (0.43) | PTPN1L3MBTL1MMEACE2ACE | |
| SCHEMBL7364721 | 1.00 | PTPN1 (0.43) | PTPN1L3MBTL1MMEACE2ACE | |
| Phosphoric Acid SCHEMBL27956600 | 0.83 | L3MBTL1 (0.55) | PTPN1L3MBTL1MME | |
| SCHEMBL7364506 | 0.83 | PTPN1 (0.43) | PTPN1L3MBTL1MMEACE2ACE | |
| SCHEMBL9545901 | 0.81 | MME (0.43) | PTPN1L3MBTL1MME | |
| SCHEMBL27947361 | 0.81 | PTPN1 (0.42) | PTPN1L3MBTL1MMEACE2ACE | |
| SCHEMBL7367519 | 0.81 | MME (0.46) | PTPN1MMEACE | |
| SCHEMBL3705739 | 0.81 | MME (0.43) | PTPN1L3MBTL1MME | |
| SCHEMBL3705736 | 0.81 | MME (0.43) | PTPN1L3MBTL1MME | |
| SCHEMBL28236616 | 0.81 | L3MBTL1 (0.52) | PTPN1L3MBTL1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327461-A1 | APELIN POLYPEPTIDES | AMGEN INC. (US) | 2024-10-03 | — | — | US | disclosed |
| US-11807693-B2 | Apelin polypeptides | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-4257152-A2 | APELIN POLYPEPTIDES | Amgen Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3674314-B1 | APELIN POLYPEPTIDES | AMGEN INC (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20220090046-A1 | Encapsulated Cells | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2022-03-24 | — | — | US | disclosed |
| EP-3907237-A1 | APJ RECEPTOR AGONISTS AND USES THEREOF | Amgen Inc. (US) | 2021-11-10 | — | — | EP | disclosed |
| EP-2935311-B1 | APJ RECEPTOR AGONISTS AND USES THEREOF | AMGEN INC (US) | 2021-03-31 | — | — | EP | disclosed |
| US-10941182-B2 | Apelin polypeptides | AMGEN INC. (US) | 2021-03-09 | — | — | US | disclosed |
| EP-3674314-A2 | APELIN POLYPEPTIDES | Amgen, Inc (US) | 2020-07-01 | — | — | EP | disclosed |
| US-10344060-B2 | Potent and selective inhibitors of Nav1.7 | AMGEN INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20140073577-A1 | POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 | AMGEN INC. (US) | 2014-03-13 | — | — | US | disclosed |
| EP-2686340-A2 | POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 | Amgen Inc. (US) | 2014-01-22 | — | — | EP | disclosed |
| WO-2012125973-A2 | POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 | AMGEN INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20120121591-A1 | SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3 | AMGEN INC. (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2432488-A2 | SELECTIVE AND POTENT PEPTIDE INHIBITORS OF KV1.3 | Amgen, Inc (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010108154-A2 | SELECTIVE AND POTENT PEPTIDE INHIBITORS OF KV1.3 | AMGEN INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| US-6307090-B1 | OXALYL ENDCAPPED; CONTAINING A BIVALENT RADICAL OF PHOSPHOTYROSINE OR A PHOSPHOTYROSINE MIMETIC | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-10-23 | — | — | US | disclosed |
| EP-0846127-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | Novartis AG (CH) | 1998-06-10 | — | — | EP | disclosed |
| WO-1997008193-A1 | ACYLATED OLIGOPEPTIDE DERIVATIVES HAVING CELL SIGNAL INHIBITING ACTIVITY | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
| WO-1997007131-A1 | ACYLATED OLIGOPEPTIDES CONTAINING PHOSPHOTYROSINE AS INHIBITORS OF PROTEIN TYROSINE KINASES | NOVARTIS AG (CH) | 1997-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344060-B2 | Potent and selective inhibitors of Nav1.7 | SCN7A, SCN9A, SCN1A | PTPN1 1292/4885L3MBTL1 1271/4885MME 1321/4885 |
| US-20140073577-A1 | POTENT AND SELECTIVE INHIBITORS OF NAV1.3 AND NAV1.7 | SCN7A, SCN3A, SCN9A | PTPN1 1378/4885L3MBTL1 1672/4885MME 1199/4885 |
| US-20120121591-A1 | SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3 | KCNJ4, KCNK4, KCNQ4 | PTPN1 1606/4885L3MBTL1 1538/4885MME 381/4885 |
| US-10941182-B2 | Apelin polypeptides | APLNR, FABP3, AP3B1 | PTPN1 1913/4885L3MBTL1 826/4885MME 62/4885 |
| US-11807693-B2 | Apelin polypeptides | APLNR, FABP3, AP3B1 | PTPN1 1913/4885L3MBTL1 826/4885MME 62/4885 |
| US-20240327461-A1 | APELIN POLYPEPTIDES | APLNR, FABP3, AP3B1 | PTPN1 1913/4885L3MBTL1 826/4885MME 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.